Sword refers to "frozen human disease" and multiple sclerosis, Lilly sacs by innovative SARM1 inhibitors

Eli Lilly and Company announced a final agreement with Disarm Therapeutics to acquire Disarm Therapeutics.
Disarm has discovered powerful and innovative SARM1 inhibitors with the goal of providing breakthrough treatments for patients with peripheral neuropathy and other neurological disorders such as amyotrophic lateral sclerosis and multiple sclerosis.
axonal degeneration is a common but unresolved pathological phenomenon in a wide range of neurological disorders that can cause severe sensations, movement and cognitive symptoms.
Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University School of Medicine in St. Louis, the co-founders of Disarm, found that SARM1 proteins are the central driver of axis mutations.
disarm's SARM1 inhibitor is designed to directly prevent the loss of axons.
SARM1 plays a key role in shaft mutations (Photo: Disarm's official website) Lilly paid $135 million in upfront payments under the terms of the agreement.
disarm equity holders may be eligible for additional milestone payments of up to $1,225 million if Lilly successfully develops and commercializes the new drugs resulting from the acquisition.
"Lilly is always looking for innovative treatments for pain and loss of function associated with nerve damage," said Dr. Mark Mintun, Lilly's vice president of pain and neurodegenerative lesions research.
we will rapidly develop their SARM1 inhibitors for the treatment of peripheral neuropathy and neurological disorders such as amyotrophic lateral sclerosis and multiple sclerosis.
"